logo
Breakthrough weight-loss drug works without nausea or vomiting, scientists reveal

Breakthrough weight-loss drug works without nausea or vomiting, scientists reveal

Independent5 days ago
A breakthrough has been made in weight-loss drugs after scientists discovered a new medication – known as TDP – that works without causing side effects of nausea or vomiting.
Millions of Americans are already using Ozempic and other GLP-1 class drugs to lose weight. While largely successful, the shots can cause uncomfortable gastrointestinal side effects.
Those symptoms and others have landed patients in emergency rooms in recent years, with 25,000 visits occurring from 2022 to 2023, according to scientists at the Centers for Disease Control and Prevention.
Researchers say the new experimental rival largely forgoes those issues although how it works to curb appetite is still being researched.
'This paper shows for the first time that giving a smaller version of octadecaneuropeptide in the periphery is still effective to improve body weight and metabolic control without side effects,' Caroline Geisler, an assistant professor at the University of Kentucky's College of Pharmacy, told Gizmodo this week.
Octadecaneuropeptide, commonly referred to as ODN, is a protein produced by brain cells called glia that support the nervous system. The researchers used ODN to create the drug TDP.
'Now we know that [glia] play a large role in sensing and communicating the status of the body, and we hope that by targeting a glial signaling molecule, we can engage many energy-regulating pathways in the brain and avoid the side effects of nausea and vomiting,' Geisler said.
In studies, the researchers inserted ODN into the hindbrain of rats, which contains the brainstem and cerebellum. The cerebellum is a part of the brain that controls movements and other cognitive processes, such as language and attention span.
Once the rats were treated with ODN, they lost weight and improved their ability to control their blood sugar. Whereas when the researchers blocked ODN, the animals showed a weaker response to treatment with the popular GLP-1 drugs.
They also dosed mice, rats, and shrews with TDN. The drug also improved blood sugar control, causing weight loss without nausea or vomiting in the rats for over a week. The shrews did not vomit either, and the drug appeared not to have effects on the animals' movement, body temperatures, and heart rate.
However, the results, published in the journal Science Translational Medicine, are only a proof of concept.
The study's authors are hoping to test the drugs in people next.
'We have an optimistic timeline that we could be ready to start clinical trials within two years,' Geisler said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wegovy maker Novo Nordisk warns of slower profits as rivals bite
Wegovy maker Novo Nordisk warns of slower profits as rivals bite

BBC News

time29 minutes ago

  • BBC News

Wegovy maker Novo Nordisk warns of slower profits as rivals bite

The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected as more "knock-off" weight-loss drugs Nordisk's share price tumbled by more than 20% as it cut its outlook and named a new chief executive to replace Lars Fruergaard Jørgensen, whose surprise exit was announced in Mike Doustdar, currently vice president of Novo Nordisk's international business, will take over on 7 August. As well as slower-than-forecast growth for Wegovy in the US obesity market, Novo Nordisk also said that sales of Ozempic to Americans with diabetes would be lower. Novo Nordisk has seen its market value tumble as other weight-loss treatments have come onto the its trading update, Novo Nordisk claimed that since May more "unsafe and unlawful" drugs have been released. The company said it "is pursuing multiple strategies, including litigation, to protect patients from knock-off 'semaglutide' drugs".Semaglutide injections are used to treat diabetes but, in recent years, have become wildly popular with people looking to lose weight, especially after the enforced lockdowns of Covid. While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts said the company had been too slow to pursue the market for people willing to pay for its weight-loss treatments. Markus Manns, a portfolio manager at Union Investment, which is a shareholder in Novo Nordisk, said that its "problems are much deeper" than Wegovy in the US and extend to the international market."Novo has underestimated the self-pay market in obesity and just recently started to focus on this important patient segment," he Manns also described the cuts to Novo's growth outlook as "a shocker". Full-year profit is now expected to expand by 10% and 16%, down from an increase of between 16% and 24% predicted in are predicted to increase by between 8% and 14%. In May, Novo forecast growth of between 13% and 21%.Benjamin Jackson, an analyst at Jeffries, questioned why Novo Nordisk has decided to appoint an internal candidate to replace Mr Jø Doustdar first joined Novo Nordisk in 1992. The company said that he had been appointed "as the result of a comprehensive process that included external and internal candidates".But Mr Jackson said: "We are surprised by the appointment of Mike Doustdar as chief executive with feedback suggesting an external candidate may have been preferred."

More than 22million Americans suffering from ADHD have higher risk of developing deadly brain disease
More than 22million Americans suffering from ADHD have higher risk of developing deadly brain disease

Daily Mail​

time29 minutes ago

  • Daily Mail​

More than 22million Americans suffering from ADHD have higher risk of developing deadly brain disease

The 22million Americans with attention-deficit/hyperactivity disorder could be more likely to develop early-onset dementia, a preliminary study suggests. Researchers at the University of Pittsburgh analyzed health records from people diagnosed with ADHD as children in the 1980s and 90s. These patients were then followed into adulthood and are now in their 40s. They found adults living with ADHD scored worse on cognitive tests looking at executive function, complex tasks, word recall and working memory. These patients also had higher levels of toxic proteins directly shown to cause Alzheimer's disease, the most common form of dementia that affects 7million Americans. The researchers said the findings of the study, which is still recruiting for larger experiments, are particularly noteworthy because participants were all under 50, suggesting early-onset disease. While they are unsure what exactly causes the elevated risks, the team suggests it could be due to individuals with ADHD having less brain capacity for age-related degeneration. They also pointed toward issues like diabetes and obesity, dementia risk factors, being more prevalent in ADHD populations. ADHD is a neurodevelopmental disorder that affects focus, impulse control, and energy levels. The CDC estimates one in 10 children in the US have been diagnosed with the condition, totaling about 7million, according to the latest data available. About 15.5million adults have the disorder. The researchers recruited 25 people who were originally part of the Pittsburgh ADHD Longitudinal Study (PALS) at the University of Pittsburgh between 1987 and 1996. Children were observed during an eight-week summer camp and diagnosed with ADHD. All of them were then followed into adulthood. The average participant age is 44 and eight in 10 are men. Participants were given blood tests to detect amyloid and tau, toxic proteins that accumulate in the brain and form plaques, destroying brain cells and causing dementia. The blood tests also measured inflammation and signs of cardiovascular disease, which can damage blood vessels and block blood flow. The researchers found participants with ADHD scored lower on tests measuring executive function and processing speed, which are how the brain handles problem solving and how quickly it takes in information. They also scored worse on working memory tests and recalled fewer words than people without ADHD. Most surprising to the researchers was higher levels of dementia-causing proteins in blood samples from ADHD patients, suggesting early signs of Alzheimer's disease. Dr Brooke Molina, study author and director of the Youth and Family Research Program at the University of Pittsburgh, said during a conference presentation: 'We found bigger differences than we expected to see at this age. Remember, the mean age is 44 and it's a fairly tight age range. These are all individuals in their early to mid 40s. 'We are seeing elevate Alzheimer's disease risk. What's going to happen with that as they age?' While it's unclear exactly why people with ADHD are at a greater risk of dementia, researchers suggest it could be because these individuals have a diminished 'brain reserve.' This means their brain's capacity to compensate for age-related changes or neurodegenerative processes is diminished, making them more vulnerable to dementia. Dr Molina also noted people with ADHD are at a higher risk of vascular conditions like high blood pressure, diabetes and obesity due to stimulant medications and a greater chance of unhealthy lifestyle factors. The experts are still recruiting for larger scale research, as the small sample size was the study's main limitation. Dr Molina said: 'There is lots more that we can do once we finish collecting the data.'

We face daunting global challenges. But here are eight reasons to be hopeful
We face daunting global challenges. But here are eight reasons to be hopeful

The Guardian

timean hour ago

  • The Guardian

We face daunting global challenges. But here are eight reasons to be hopeful

Don't fret the future. A lot of people do, and for powerful reasons – we are facing enormous challenges unprecedented in human history, from climate change and nuclear war to engineered pandemics and malicious artificial intelligence. A 2017 survey showed that nearly four in 10 Americans think that climate change alone has a good chance of triggering humanity's extinction. But we seem largely blind to the many profound reasons for hope – and it's not entirely our fault. Humans are wired with a 'negativity bias' that triggers a stronger emotional response to bad news than good news – evident in the journalism maxim 'if it bleeds, it leads'. This loss-aversion behavior served a purpose in our evolutionary past, when information and resources were scarce, but in the age of endless information access, it can lead to pessimism, anxiety and a distorted vision of what humanity is capable of. In reality, we are making incredible progress in global poverty, health, longevity, climate change and much more, but these trends are harder to perceive because they accumulate gradually and quietly. As the Wired magazine founder Kevin Kelly points out, progress is often about what doesn't happen – the children who won't die of smallpox, or the farmers whose crops won't get raided. The world is still an awful place in many ways, and the crises we face are daunting. But looking past the dark headlines, we can see bright trendlines that give us profound reasons to be optimistic for our future. Just a decade ago or so, it appeared that civilization was on a course to cause a disastrous 4C-5C of warming above pre-industrial levels. But since then, major nations and markets have responded with surprising force and urgency; global carbon dioxide emissions have significantly slowed, and in many countries, per capita emissions are falling even while per capita GDP and energy use are going up. We are still not doing enough – there is a lingering risk of runaway carbon cycle feedback loops that could push us over 4C – but nations are making ambitious net-zero commitments that, if realized, could feasibly keep warming below 2C. The pathway for avoiding the absolute worst outcomes – humanity's extinction, for one – is increasingly clear and doable, and involves a combination of decarbonization, renewable energy breakthroughs, responsible geoengineering and carbon dioxide removal. The central reason for optimism, however, remains the coming age of radically cheap renewable energy, primarily from solar photovoltaics. The exponential growth in solar energy has stunned even expert forecasters. In 2015, the International Energy Agency predicted that the world would add about 35 gigawatts of solar energy capacity by 2023. Their estimate was off by a factor of 10. The costs of solar have fallen below the cost of coal, a tipping point that will financially incentivize markets to go green even in the absence of policy pressures. There are strong reasons to believe this exponential progress will continue; soon it could become cheaper to create fuel out of thin air and water using solar energy than to drill for it underground. More signs of an energy revolution are all around: The same expert-defying growth is happening in the adoption of electric vehicles, and global investment in clean energy now far outstrips that of fossil fuels. With worldwide access to radically cheap renewable energy and carbon-neutral fuels, underdeveloped countries can achieve first-world standards of living without a corresponding increase in carbon emissions. Already wealthy nations will see new waves of growth as energy abundance triggers new economic possibilities, including affordable desalination, which could address water shortages in many parts of the world. We may be on the verge of a new industrial revolution and a new era of human prosperity. As the Harvard psychologist Steven Pinker points out, you've never seen a newspaper run the headline '137,000 people escaped from extreme poverty yesterday' – yet this incredible statistic has been accurate every day for decades now. Since 1990, more than a billion people have been lifted out of extreme poverty, with the impoverished share falling from 38% of the global population down to 9.1% today. That still leaves more than 600 million people living below the international poverty line of $2.15 a day, making it clear that the fight is far from over. But with energy abundance driving new growth and economic modalities, we can expect to see the downward trend continue; ultimately, we should strive for no less than a 0% rate of poverty globally. Further progress is there for the taking. It might be the most feelgood statistic of all time: an average person born today can expect to live more than twice as long as someone born around 1900. In South Korea, life expectancy has more than tripled, surging from just 23.5 years in 1908 to more than 83 years today. This dramatic increase is thanks to huge advances in medicine, public health and living standards, but also by a stunning fall in child mortality: for most of human history, about half of all children died before their 15th birthday; today the figure is less than 5% globally and as low as 0.4% in some wealthy nations. We can, and probably will, save millions of children's lives by driving the global rate this low – a feasible and morally urgent goal for the 21st century. On top of all this progress, advances in ageing biology are leading to breakthroughs in slowing the ageing process and keeping laboratory animals healthier for longer. We now have numerous ways of accomplishing this with mice and primates; what is needed is an injection of funding to bring these experiments to human trials. Ageing is responsible for about two-thirds of all deaths; channeling our resources to lessen its tragic effects will have enormous and immediate benefits to human society. If the funding does come, the next few decades could get very interesting. Converging advancements in AI and biotechnology are pointing toward a radical enhancement of human health and wellbeing. Already, projects like Google's AlphaFold are discovering structures of pathogens and potential treatments for cancer much faster than humans could. New gene-editing tools like Crispr have the potential to cure many of the more than 10,000 diseases that are caused by single-gene mutations. Barney Graham, an immunologist who played a pivotal role in developing mRNA vaccines, puts it thusly: 'You cannot imagine what you're going to see over the next 30 years. The pace of advancement is in an exponential phase right now.' In the coming decades, we could potentially gain the power to regenerate limbs, engineer designer life forms, eliminate all disease and possibly extend our life spans indefinitely. If you've ever watched two-legged robots navigating obstacle courses and landing synchronized backflips, you are familiar with the incredible developments in robotics over the past decade. But the real reason to get excited now is not the leaps in physical capabilities (save for the potential of a future robot Olympics), but in intellectual abilities. OpenAI, creators of ChatGPT, has partnered with Figure, a robotics startup, to incorporate multimodal artificial intelligence into a humanoid form factor. Their walking, talking full-body robots are learning tasks merely by watching videos – no manual training required. Tesla's Optimus bot is a direct competitor that its CEO, Elon Musk, believes will eventually be more valuable than the company's electric car business. It's not hard to see the value: humanoid robots could address acute labor shortages and replace labor-intensive and dangerous jobs, taking on roles in disaster response, healthcare, manufacturing, space exploration and much more – freeing real people to pursue more desirable jobs, elevating quality of life and boosting economic growth. Of course, humanity will only benefit if we can address the risks of job displacement and human safety. Half of the battle will be controlling these risks and ensuring we reap the benefits, rather than be overcome by armies of terminators. For decades, the final frontier was only accessible to a handful of major nations with mainly geopolitical interests. But in the past 10-15 years, launch costs have fallen drastically thanks to the advent of reusable rockets and innovative fuel types, enabling a new generation of space technologies and opening up the final frontier to a wave of commercial and scientific interests. Satellite broadband is starting to bring internet access to rural and underdeveloped parts of the world, which will bolster agriculture, education, health, economic opportunity and participation in democracy. Low-gravity environments are uniquely ideal for cell research, where scientists are growing miniature organs for study, and could lead to pharmaceutical breakthroughs. Eventually, bolder prospects like asteroid mining could supply trillions of dollars' worth of rare materials without compromising environments back on Earth. You can almost feel the pace quickening: this decade has already seen twice as many moon missions as the 2010s. Plans for commercial space stations like Orbital Reef and Starlab are under way and slated to be operational before 2030. Nasa has plans to put humans on the moon again as soon as 2026. To top it all off, the recently launched James Webb space telescope is already discovering new secrets of the universe only two years into its mission. It's finding water vapor on alien planets and holds the promise of detecting signatures of alien life. We may be on the verge of the most significant scientific discovery of all time. It's safe to say that a new space age has arrived. It's not far-fetched to speculate that a major disaster may await us in the coming centuries. But humans have a long history of rebounding from catastrophic collapse. Our ancestors have survived asteroid impacts, ice ages, supervolcano eruptions and deadly plagues – each time eventually bouncing back to new heights. The Black Death of 1347 killed up to half the population of Europe and one out of every 10 people globally. But even this did not derail human progress in the long term, and it was followed by the scientific revolution just 200 years later. The upward march of humanity has never been and will never be perfectly smooth, but progress is unmistakable over the long term. It will take a truly apocalyptic sequence of events to stop us. The modern world was built and shaped by optimists. We owe it to them to carry the torch. Optimism for the future is not only justified – it's a weapon in the fight for a higher future, and a moral obligation to ourselves and to future generations. No future is guaranteed; there will be injustices and suffering in every path forward, just as there have been forever. A utopia will never be achievable, but in striving to reach it, we can create the best possible world for us and our descendants. The larger the problems we face, the greater the opportunity for progress; the immense challenges of the 21st century can be the catalyst for a new leap in the human condition to heights we cannot yet imagine. We have everything we need to thrive. Our resiliency will protect us; our intelligence will propel us. If there is one lesson our history can teach us, it's to never underestimate the human race. Illustrations by Seba Cestaro John D Boswell is a film-maker, composer, visual effects artist and editor

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store